top of page
Molecular Testing in Thyroid Cancer: Emerging Biomarkers RET and NTRK

Molecular Testing in Thyroid Cancer: Emerging Biomarkers RET and NTRK

Play Video

Molecular Testing in Thyroid Cancer: Emerging Biomarkers RET and NTRK

December 8th, 2021

Cohen-Ezra head shot.jpg

Ezra E.W. Cohen, MD, FRCPSC, FASCO

Ezra Cohen, MD, is Chief of the Division of Hematology‐Oncology, and Co‐Director of the San Diego Center for Precision Immunotherapy. A physician‐scientist, Dr. Cohen led an independently funded laboratory interested in mechanisms of action of novel therapeutics. He has made major contributions to targeted and immunotherapy. His research has received peer‐reviewed funding in the study of epidermal growth

factor receptor inhibitors, cell therapy, and immunotherapy in head and neck
cancer. He has made major contributions to the understanding of critical signaling
pathways, integration of novel agents into standard of care, and definition of
mechanisms to overcome resistance to drug therapy. He has also recently
co‐developed a personalized neoantigen vaccine using unique cancer mutations to
boost an anti‐tumor immune response.


Dr. Cohen is the Associate Director for Translational Science and leader of the Solid Tumor Therapeutics research program at Moores Cancer Center. He brings his expertise and preeminent reputation in head and neck cancer research and patient care to solid tumor therapeutics. Among other roles, he is chair of the Protocol Review and Monitoring Committee (PRMC) and serves as a member of the Cancer Council, and the Cancer Center’s Executive Committee.


Dr. Cohen recently served as editor‐in‐chief of Oral Oncology, the highest impact specialty journal in head and neck cancer, and currently serves as senior editor for Clinical Cancer Research. He has been the principal investigator on multiple studies of novel agents in head and neck cancer and other solid tumors in all phases of development including chemoprevention, phase I, II, and III trials. Dr. Cohen has authored more than 170 papers and has presented his research at national and international meetings. In addition, he has served as a grant reviewer for the NIH, American Association for Cancer Research, American Society of Clinical Oncology, and the Ontario Institute for Cancer Research.


Dr. Cohen completed residencies in Family Medicine at the University of Toronto and in Internal Medicine at Albert Einstein College of Medicine. He completed a Hematology/Oncology fellowship at the University of Chicago where he was named chief fellow. Prior to his arrival in San Diego, Dr. Cohen was Co‐Director of the Head and Neck Cancer Program, Associate Director for Education and Program Director for the Hematology/ Oncology Fellowship at the University of Chicago Comprehensive Cancer Center. A dedicated educator, Dr. Cohen also mentored and developed young faculty in his program.

Testing for RET is provided by Lighthouse, a Celerity Biosciences Subsidiary, and Funded by Loxo Oncology at Lilly

bottom of page